LanZhou Foci Pharmaceutical Co.,Ltd.

Symbol: 002644.SZ

SHZ

7.96

CNY

Market price today

  • 70.4765

    P/E Ratio

  • -2.4425

    PEG Ratio

  • 4.06B

    MRK Cap

  • 0.01%

    DIV Yield

LanZhou Foci Pharmaceutical Co.,Ltd. (002644-SZ) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.32%

Operating Profit Margin

0.06%

Net Profit Margin

0.05%

Return on Assets

0.02%

Return on Equity

0.03%

Return on Capital Employed

0.04%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Yingchun Wang
Full-time employees:1353
City:Lanzhou
Address:68 Foci Street
IPO:2011-12-22
CIK:

LanZhou Foci Pharmaceutical Co.,Ltd., a pharmaceutical company, manufactures and sells traditional Chinese medicines in China. It offers its products in various dosage forms, including pills, tablets, capsules, and granules under the Min Shan and Foci brands. The company also engages in researching activities for the development of new herbal drugs. It also exports its products to approximately 27 countries, which include the United States, Canada, Japan, Australia, Russia, Ukraine, Singapore, Indonesia, Thailand, Malaysia, New Zealand, Hong Kong, etc. The company was founded in 1929 and is based in Lanzhou, China. LanZhou Foci Pharmaceutical Co.,Ltd. is a subsidiary of Lanzhou Foci Pharmaceutical Factory.

General Outlook

When we look at how much money they make before expenses, they keep 0.323% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.064%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.051%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.023% return, is a testament to LanZhou Foci Pharmaceutical Co.,Ltd.'s adeptness in optimizing resource deployment. LanZhou Foci Pharmaceutical Co.,Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.033%. Furthermore, the proficiency of LanZhou Foci Pharmaceutical Co.,Ltd. in capital utilization is underscored by a remarkable 0.035% return on capital employed.

Stock Prices

LanZhou Foci Pharmaceutical Co.,Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $8.14, while its low point bottomed out at $8. This variance in figures offers investors a lucid insight into the roller-coaster ride that is LanZhou Foci Pharmaceutical Co.,Ltd.'s stock market.

Liquidity Ratios

Analyzing 002644.SZ liquidity ratios reveals its financial health of the firm. The current ratio of 270.94% gauges short-term asset coverage for liabilities. The quick ratio (180.59%) assesses immediate liquidity, while the cash ratio (79.01%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio270.94%
Quick Ratio180.59%
Cash Ratio79.01%

Profitability Ratios

002644.SZ profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 6.25% underscores its earnings before tax deductions. The effective tax rate stands at 15.97%, revealing its tax efficiency. The net income per EBT, 82.32%, and the EBT per EBIT, 97.23%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 6.43%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin6.25%
Effective Tax Rate15.97%
Net Income per EBT82.32%
EBT per EBIT97.23%
EBIT per Revenue6.43%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.71, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 231.40% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding181
Days of Inventory Outstanding181
Operating Cycle338.88
Days of Payables Outstanding145
Cash Conversion Cycle194
Receivables Turnover2.31
Payables Turnover2.51
Inventory Turnover2.01
Fixed Asset Turnover1.08
Asset Turnover0.45

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 0.11, and free cash flow per share, 0.10, depict cash generation on a per-share basis. The cash per share value, 0.68, showcases liquidity position. A payout ratio of 0.03 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.05, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share0.11
Free Cash Flow per Share0.10
Cash per Share0.68
Payout Ratio0.03
Operating Cash Flow Sales Ratio0.05
Free Cash Flow to Operating Cash Flow Ratio0.84
Cash Flow Coverage Ratio2.20
Short Term Coverage Ratio2.33
Capital Expenditure Coverage Ratio6.41
Dividend Paid and Capex Coverage Ratio5.41
Dividend Payout Ratio0.01

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 1.03%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.01, we discern the balance between debt and equity financing. The long-term debt to capitalization, 0.08%, and total debt to capitalization, 1.46%, ratios shed light on its capital structure.

cards.indicatorcards.value
Debt Ratio1.03%
Debt Equity Ratio0.01
Long Term Debt to Capitalization0.08%
Total Debt to Capitalization1.46%
Cash Flow to Debt Ratio2.20
Company Equity Multiplier1.43

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 2.28, provides a glimpse into top-line earnings distributed across each share. Net income per share, 0.13, reflects the portion of profit attributed to each share. The book value per share, 3.42, represents the net asset value distributed per share, while the tangible book value per share, 3.29, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share2.28
Net Income Per Share0.13
Book Value Per Share3.42
Tangible Book Value Per Share3.29
Shareholders Equity Per Share3.42
Interest Debt Per Share0.05
Capex Per Share-0.04

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 14.12%, indicates top-line expansion, while the gross profit growth, 26.23%, reveals profitability trends. EBIT growth, -40.26%, and operating income growth, -40.26%, offer insights into operational profitability progression. The net income growth, -38.16%, showcases bottom-line expansion, and the EPS growth, -38.10%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth14.12%
Gross Profit Growth26.23%
EBIT Growth-40.26%
Operating Income Growth-40.26%
Net Income Growth-38.16%
EPS Growth-38.10%
EPS Diluted Growth-38.10%
Weighted Average Shares Growth-0.02%
Weighted Average Shares Diluted Growth-0.02%
Dividends per Share Growth293.96%
Operating Cash Flow Growth-9.20%
Free Cash Flow Growth40.11%
10-Year Revenue Growth per Share247.02%
5-Year Revenue Growth per Share113.56%
3-Year Revenue Growth per Share74.14%
10-Year Operating CF Growth per Share645.67%
5-Year Operating CF Growth per Share79.22%
3-Year Operating CF Growth per Share4.51%
10-Year Net Income Growth per Share91.00%
5-Year Net Income Growth per Share-7.87%
3-Year Net Income Growth per Share-37.79%
10-Year Shareholders Equity Growth per Share115.83%
5-Year Shareholders Equity Growth per Share21.16%
3-Year Shareholders Equity Growth per Share10.34%
10-Year Dividend per Share Growth per Share182.52%
5-Year Dividend per Share Growth per Share320.90%
3-Year Dividend per Share Growth per Share-12.44%
Receivables Growth-16.09%
Inventory Growth5.51%
Asset Growth-2.26%
Book Value per Share Growth1.77%
Debt Growth81.15%
R&D Expense Growth31.29%
SGA Expenses Growth49.56%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 4,597,951,724.25, captures the company's total value, considering both debt and equity. Income quality, 0.96, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.02, gauges operational efficiency, while the research and development to revenue, 2.66%, highlights investment in innovation. The ratio of intangibles to total assets, 3.50%, indicates the value of non-physical assets, and capex to operating cash flow, -34.20%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value4,597,951,724.25
Income Quality0.96
Sales General and Administrative to Revenue0.02
Research and Development to Revenue2.66%
Intangibles to Total Assets3.50%
Capex to Operating Cash Flow-34.20%
Capex to Revenue-1.93%
Capex to Depreciation-42.82%
Graham Number3.18
Return on Tangible Assets2.75%
Graham Net Net0.29
Working Capital771,181,812
Tangible Asset Value1,679,868,853
Net Current Asset Value479,197,043
Average Receivables484,177,765.5
Average Payables310,709,021
Average Inventory360,063,727
Days Sales Outstanding139
Days Payables Outstanding141
Days of Inventory On Hand168
ROIC3.92%
ROE0.04%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 2.32, and the price to book ratio, 2.32, reflect the market's valuation relative to the company's book value. The price to sales ratio, 3.62, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 84.30, and price to operating cash flows, 71.16, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio2.32
Price to Book Ratio2.32
Price to Sales Ratio3.62
Price Cash Flow Ratio71.16
Price Earnings to Growth Ratio-2.44
Enterprise Value Multiple39.36
Price Fair Value2.32
Price to Operating Cash Flow Ratio71.16
Price to Free Cash Flows Ratio84.30
Price to Tangible Book Ratio2.85
Enterprise Value to Sales3.95
Enterprise Value Over EBITDA30.27
EV to Operating Cash Flow69.97
Earnings Yield1.35%
Free Cash Flow Yield0.87%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ) on the SHZ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 70.477 in 2024.

What is the ticker symbol of LanZhou Foci Pharmaceutical Co.,Ltd. stock?

The ticker symbol of LanZhou Foci Pharmaceutical Co.,Ltd. stock is 002644.SZ.

What is company IPO date?

IPO date of LanZhou Foci Pharmaceutical Co.,Ltd. is 2011-12-22.

What is company current share price?

Current share price is 7.960 CNY.

What is stock market cap today?

The market cap of stock today is 4064829720.000.

What is PEG ratio in 2024?

The current -2.443 is -2.443 in 2024.

What is the number of employees in 2024?

In 2024 the company has 1353.